Astrocytomas are brain tumors originating from supportive cells called astrocytes. They make up about half of all brain tumors and can vary in severity. Causes include genetic mutations and environmental exposures like radiation. Symptoms depend on tumor size and location, including headaches, seizures, and neurological issues. Treatment involves surgery, radiation, and chemotherapy, with personalized care essential. Understanding the risks and management strategies can improve patient outcomes.

Astrocytomas are a type of glioma tumor that develop in the brain and spinal cord, originating from astrocytes—cells that assist nerve communication, maintain the blood-brain barrier, and support synapse formation. They account for roughly half of all brain tumor cases and demand accurate diagnosis and treatment. Although the exact cause is unclear, factors such as radiation exposure and genetic mutations, particularly in the IDH1 gene, are considered risk factors. Individuals with conditions like Li-Fraumeni syndrome, neurofibromatosis type 1, or tuberous sclerosis face increased risk. Symptoms depend on tumor size and location, encompassing headaches, seizures, neurological deficits, vision problems, and balance disturbances. Astrocytomas are graded from I (less aggressive) to IV (most aggressive), including pilocytic, diffuse, anaplastic, and glioblastoma types. Treatment options range from surgical removal and radiation to chemotherapy, targeted therapies, or tumor-treating electrical fields. Supportive care involves staying informed, maintaining a healthy lifestyle, building social connections, goal setting, and preparing for ongoing management under medical guidance.